Work

The integration of artificial intelligence and biotechnology in medicine: accelerating novelty in biomarker-targeted discovery and drug delivery systems

Year: 2025

Type: article

Abstract: Biotechnology and artificial intelligence (AI) are two transformative fields converging to benefit STEM because of their reliance on data and models. The tools from both fields have redefined and improved translational performance of laboratory investigations on drug discovery, design, development and delivery for personalized treatment. Although the long term merit of this integration of AI in biotechnology outweighs the demerit but is the current trend suitable in application for drug delivery systems (DDS) upgrades. In this article, we indicated how some key AI-biotech research is supporting accelerated novelty in biomarker-targeted discovery and DDS for disease management rather than merely incremental changes in 21st century. • Biotechnology and artificial intelligence (AI) are reliant on data and models. • Both tools have improved field investigations on drug discovery and delivery. • These two giants are accelerating novelty rather than redundancy in 21st century.

Source: Advances in Biomarker Sciences and Technology

DOI: 10.1016/j.abst.2025.12.002

Authors: Christopher Busayo Olowosoke, Daniel Ogbonnaya Nwankwo, Chinedu Shedrach Izu, Prosper Obed Chukwuemeka

Institutions: Federal University of Technology, RMIT University, University of Colorado Boulder, University of Benin

Language: English

Topic: Computational Drug Discovery Methods

Subfield: Computational Theory and Mathematics

Field: Computer Science

Domain: Physical Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $700